Primary Profile

Eli Lilly Canada Inc.

Eli Lilly Canada Inc.

Eli Lilly Canada Inc.

3650 Danforth Ave
Scarborough, Ontario
M1N 2E8

3650 Danforth Ave
Scarborough, Ontario
M1N 2E8

(416) 694-3221

(416) 699-7252

Click here

Eli Lilly Canada Inc.

Lilly is committed to providing answers that matter in medicine, life sciences and health care. As a leading inovation-driven corporation, Lilly is developing a growing portfolio of products by applying the latest research from its own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools and by providing exceptional service to its customers.

Company Details





325410 - Pharmaceutical and Medicine Manufacturing

541710 - Research and Development in the Physical, Engineering and Life Sciences

Manufacturer / Processor / Producer

Product / Service / Licensing

Product Name: Zyprexa (olanzapine)
Zyprexa (olanzapine) is a medication in a class of medicines called atypical antipsychotics. It is approved for the treatment of schizophrenia and related psychotic disorders; the treatment of acute bipolar manic and mixed episodes; and the first-line maintenance treatment of bipolar disorder. It is also available in an intramuscular formulation called Zyprexa IntraMuscular (olanzapine tartrate for injection) for the rapid control of agitation in patients with schizophrenia and related psychotic disorders; and for agitation in bipolar mania. It is also available in a formulation that rapidly dissolves in a patient’s mouth called Zyprexa Zydis.

Product Name: Humalog (insulin lispro injection [rDNA origin])
Humalog (insulin lispro injection [rDNA origin]) is a mealtime insulin that offers control, flexibility and convenience. Its unique rapid action mimics the body’s own insulin after meals.

Product Name: Gemzar (gemcitabine)
Gemzar (gemcitabine) belongs to a class of drugs known as antimetabolites. It is approved as a single agent for the treatment of advanced pancreatic cancer; as a single agent or in combination with cisplatin for advanced non-small-cell lung cancer; in combination with cisplatin for the treatment of metastatic bladder cancer; and in combination with paclitaxel for the treatment of metastaic breast cancer.

Product Name: ReoPro (abciximab)
ReoPro (abciximab) is a medication in a class of potent anti-platelet drugs known as glycoprotein IIb/IIIa inhibitors. These compounds prevent clots from forming in the arteries and the treatment
of coronary artery blockage and prevention of restenosis.

Product Name: Evista (raloxifene hydrochloride)
Evista is a non-hormonal osteoporosis therapy called a Selective Estrogen Receptor Modulator (SERM) and is approved for the prevention and treatment of osteoporosis.

Product Name: Alimta (pemetrexed)
Alimta (pemetrexed) is a multi-targeted anti-cancer drug for use with cisplatin, a standard chemotherapy agent, in the treatment of malignant pleural mesothelioma (MPM) in patients whose disease is either unresectable, unable to be surgically removed, or who are not candidates for curative surgery. MPM is a cancer of the lining of the lungs often associated with asbestos exposure. Alimta is also approved for the treatment for patients with nonsquamous non-small cell lung cancer (NSCLC) after prior chemotherapy and for use in combination with cisplatin for the initial treatment of NSCLC.

Product Name: Cialis (tadalafil)
Cialis (tadalafil) is an oral medication for the treatment of erectile dysfunction. It belongs to the class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors.

Product Name: Forteo (teriparatide [rDNA origin] injection)
Forteo (teriparatide [rDNA origin] injection) is a medication in a new class of osteoporosis treatments called bone formation agents. It is indicated for the treatment of postmenopausal women with severe osteoporosis who are at high risk of fracture or who have failed or are intolerant to previous osteoporosis therapy. Forteo is also indicated to increase bone mass in men with primary or low testosterone severe osteoporosis who have either failed or are intolerant to previous osteoporosis therapy. It was also the first in the class to be approved for the treatment of osteoporosis associated with glucocorticoid therapy in men and women who are at high risk for bone fracture.

Product Name: Humatrope (somatropin [rDNA origin] for injection)
Humatrope (somatropin [rDNA origin] for injection) is a biosynthetic growth hormone with the same chemical structure as the growth hormone produced by the human pituitary gland. Humatrope (somatropin rDNA origin) is approved for the treatment of growth hormone deficiency in children, for use in adult replacement therapy and for treatment in girls with short stature due to Turner Syndrome. It is also approved for the long-term treatment of Idiopathic Short Stature and for the treatment of short stature or growth failure in children with short stature homeobox-containing gene (SHOX) deficiency whose epiphyses are not closed. Humatrope is also approved for the treatment of short stature in children born small for gestational age, who have not achieved catch up growth by the age of 2 years.

Product Name: Humulin (insulin, human biosynthetic)
Humulin (insulin, human biosynthetic) family of insulins includes Humulin N, Humulin R and Humulin 30/70. The different formulations vary in the onset and duration of action. A synthetic insulin that is identical in chemical structure to the insulin naturally produced by the pancreas, Humulin is made by a chemical process called recombinant DNA technology.

Product Name: Strattera (atomoxetine)
Strattera (atomoxetine), a non-stimulant, is approved for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in children six years of age and over, adolescents and adults.

Product Name: Xigris (drotrecogin alfa [activated])
Xigris (drotrecogin alfa [activated]) is approved for the reduction of mortality in adult patients with severe sepsis who have a high risk of death, when added to current best practice.

Product Name: Cymbalta (duloxetine hydrochloride)
Cymbalta (duloxetine hydrochloride) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is approved for adults age 18 and older for the acute treatment of major depressive disorder (MDD) and for the management of diabetic peripheral neuropathic pain (DPNP). It is also approved as a treatment for generalized anxiety disorder, the management of pain associated with fibromyalgia, and for maintenance of response of MDD.

Product Name: Adcirca (tadalafil)
Adcirca (tadalafil) is approved for the treatment of idiopathic (“primary”) pulmonary arterial hypertension (PAH) or PAH associated with connective tissue disease, congenital heart disease or anorexigen use in patients with WHO functional class II or III who have not responded to conventional therapy. PAH is also known as high blood pressure in the arteries of the lungs.

Product Name: Effient (prasugrel hydrochloride)
Effient (prasugrel hydrochloride) is an oral antiplatelet medicine specifically for patients undergoing an angioplasty procedure (also known as percutaneous coronary intervention or PCI) to open up a blocked heart artery.

Contact Information

Marcel Lechanteur
Title: General Manager
Telephone: (416) 694-3221
Fax: (416) 694-0487

Terry McCool
Title: Vice President
Area of Responsibility: Government Relations
Telephone: (416) 694-3221
Fax: (416) 693-3604